[2014/05/09] Taipei, Taiwan, R.O.C. – InnoPharmax Inc. announced that the Company's abstract on Gemcitabine HCl Oral Formulation (D07001-F4) has been accepted for poster presentation at the 2014 American Society of Clinical Oncology (“ASCO”) Annual Meeting. The annual ASCO meeting will be held in Chicago, Illinois from May 30 through June 3, 2014.
The Company's abstract titled, “Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors.,” is selected for presentation during the “General Poster Session: Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics” portion of the symposium among 5,500 submissions for poster consideration at this year's meeting. The authors of the poster presentation include clinical physicians and staffs involved in the study from National Taiwan University Hospital and National Cheng Kung University Hospital, along with InnoPharmax colleagues.
“We are proud to have been selected to present our research on D07001-F4 to the scientific community at ASCO, especially considering the large number of applicants this year,” commented Dr. CS Hsu, President of InnoPharmax. “Along with the poster section, we are particularly pleased to participate the exhibition at this year's ASCO meeting since it is a fantastic platform for us to share the research. Welcome to visit us at booth #20154.”
2014 ASCO Annual Meeting
Date: May 30 – June 3, 2014
Venue: McCormick Place, Chicago, Illinois, US
Booth number: 20154
Contact person: Eric Shee
About Gemcitabine Hydrochloride Oral Formulation (D07001-F4)
Gemcitaine (2',2'-difluorodeoxycytidine) is a fluorine-substituted deoxycytidine analog with a broad spectrum of antitumor activity. It is rapidly and extensively deaminated by cytidine deaminase to the inactive metabolite, 2',2'-difluorodeoxyuridine (dFdU). It has been reported in a reported clinical study that the systemic exposure to oral gemcitabine was low due to extensive firstpass metabolism to dFdU.
D07001-F4 was developed based on InnoPharmax's proprietary formulations to overcome the problem of low bioavailability of oral gemcitabine. In dog pharmacokinetic study, gemcitabine was well absorbed from the D07001-F4 formulation with oral bioavailability over 70%. Preclinical studies have shown that D07001-F4 shows efficacy in pancreatic as well as other selected tumor models.
About InnoPharmax
InnoPharmax is a specialty pharmaceutical company focused in the development and commercialization of products for the treatment of infectious diseases, immunology and oncology. It develops and acquires potential drug candidates for further development as well as commercialization, and uses internally developed drug delivery technology platforms for improving the safety and effectiveness of currently available drugs to provide better medical choices in these specific disease categories.
